Literature DB >> 15816011

Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms.

R M Milani1, A C Parrott, F Schifano, J J D Turner.   

Abstract

Cannabis is one of the most common 'co-drugs' for ecstasy users. The aim of the present study was to explore self-reported psychobiological problems in ecstasy polydrug users in relation to their pattern of cannabis use. Two hundred and eighty ecstasy polydrug users were allocated into five cannabis groups according to the frequency of their cannabis use. The control group comprised 121 alcohol-tobacco users. There were no significant group differences with regard to age, diagnosed family psychiatric history and level of self-rated stress experienced during 6 months prior to the study. The present study produced three main findings: (a) Ecstasy users with no concomitant use of cannabis displayed more self-rated aggression and somatic symptoms compared with ecstasy users who were smoking cannabis on a monthly or weekly basis. (b) Ecstasy users who reported heavy cannabis use in the past displayed higher paranoid symptoms compared with ecstasy weekly and daily cannabis users. (c) Former heavy cannabis users were the most likely to complain of a variety of ecstasy related long-term problems. In conclusion, moderate cannabis use may help to ameliorate or mask MDMA-induced aggressivity and somatic symptoms. However, this study confirms that heavy cannabis and ecstasy use is associated with several psychobiological problems, which may emerge after a period of abstinence from both drugs. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816011     DOI: 10.1002/hup.684

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  10 in total

1.  Ecstasy use and suicidal behavior among adolescents: findings from a national survey.

Authors:  Jueun Kim; Bin Fan; Xinhua Liu; Nancy Kerner; Ping Wu
Journal:  Suicide Life Threat Behav       Date:  2011-06-01

2.  Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy.

Authors:  Lynn T Singer; Derek G Moore; Sarah Fulton; Julia Goodwin; John J D Turner; Meeyoung O Min; Andrew C Parrott
Journal:  Neurotoxicol Teratol       Date:  2012-03-03       Impact factor: 3.763

3.  Are ecstasy users biased toward endorsing somatic mental health symptoms? Results from a general community sample.

Authors:  Amanda M George; Tim D Windsor; Bryan Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2010-12-08       Impact factor: 4.530

4.  In-utero exposure to the popular 'recreational' drugs MDMA (Ecstasy) and Methamphetamine (Ice, crystal): preliminary findings.

Authors:  Derek G Moore; John J D Turner; Julia E Goodwin; Sarah E Fulton; Lynn T Singer; Andrew C Parrott
Journal:  Clin Dev Med       Date:  2011-02

5.  THC Prevents MDMA Neurotoxicity in Mice.

Authors:  Clara Touriño; Andreas Zimmer; Olga Valverde
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

6.  During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: initial findings from the Development and Infancy Study.

Authors:  Derek G Moore; John D Turner; Andrew C Parrott; Julia E Goodwin; Sarah E Fulton; Meeyoung O Min; Helen C Fox; Fleur M B Braddick; Emma L Axelsson; Stephanie Lynch; Helena Ribeiro; Caroline J Frostick; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2009-11-25       Impact factor: 4.153

Review 7.  Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users.

Authors:  A C Parrott
Journal:  Neuropsychobiology       Date:  2009-11-05       Impact factor: 2.328

Review 8.  Relevance of rodent models of intravenous MDMA self-administration to human MDMA consumption patterns.

Authors:  R De La Garza; K R Fabrizio; A Gupta
Journal:  Psychopharmacology (Berl)       Date:  2006-02-10       Impact factor: 4.530

9.  Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes.

Authors:  A C Parrott; J Lock; A C Conner; C Kissling; J Thome
Journal:  Neuropsychobiology       Date:  2008-07-24       Impact factor: 2.328

Review 10.  Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users.

Authors:  A C Parrott; R M Milani; E Gouzoulis-Mayfrank; J Daumann
Journal:  J Neural Transm (Vienna)       Date:  2007-05-24       Impact factor: 3.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.